王永辉

药物化学, 研究员, 博士生导师


姓名
王永辉
性别
 男

职称
研究员
学历
 博士

电话

传真


电子邮件
yonghuiwang@fudan.edu.cn
个人主页


通讯地址
上海市浦东新区张衡路826号


教育经历
1997.08 – 2001.08美国哈佛大学化学和化学生物学系，有机化学专业，博士后
1993.08 – 1997.08美国弗吉尼亚理工大学化学系，有机化学专业，博士
1983.09 – 1985.12东北大学化学系，分析化学专业，硕士
1979.09 – 1983.07河南师范大学化学系，化学专业，学士
工作经历
2014.01 – 现在 复旦大学药学院，特聘研究员、博士生导师；上海市药物研发协同创新中心，化学部主任
2008.10 – 2013.12葛兰素史克制药公司(上海)研发中心，副总监
2001.08 – 2008.10 葛兰素史克制药公司(美国费城)研发中心，研究员
1985.12 – 1993.08 西安建筑科技大学环境工程学院，助教、讲师

研究方向
1. 炎症免疫小分子药物发现
2. 靶向抗癌小分子药物发现
3. 基于表型筛选的小分子药物发现


代表性论著
1.Discovery of biaryl amides as potent, orally bioavailable and CNS penetrant ROR?t inhibitors. ACS Med. Chem. Lett.,2015,6, 787-792 (1st and corresponding author).
2.Discovery of N-(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent ROR?t inverse agonists.Bioorg. Med. Chem2015, 23, 5293-5302(1st and corresponding author).
3.Small molecule ROR?t antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. Immunity2014, 40, 477-489 (4th author)
4.Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides andN-(5-(arylcarbonyl)thiophen-2-yl)amides as potent ROR?t inhibitors. Bioorg. Med. Chem.2014, 22, 692-702. (1st and corresponding author)
5.Discovery of tertiary amine and indolederivatives as potent ROR?tinverse agonists. ACS Med. Chem. Lett.2014, 5, 65-68. (corresponding author)
代表性专利
1.Preparation of N-substituted 2-[4-(ethylsulfonyl)phenyl]acetamides as retinoid-related orphan receptor gamma modulators. WOA1, Published on 03/07/2013
2.Preparation of thiazole derivatives as modulators of retinoid-related orphan receptor gamma. WOA1; Published on 03/08/2012
3.N-Glycinylpyridinedicarboxamide derivatives as HIF prolyl hydroxylase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of anemia. WOA1, Published on 12/30/2009; USA1/ EP**A1/ JPT, applied on 2011
4.Preparation of aminosulfonyl-N-thiadiazolylbenzamide for use as IL-8 receptor Antagonists. WOA1 , Published on 06/12/2008; US**B2, granted on 10/25/2011
5.Preparation of N-[(piperazinylmethyl)biphenyl]benzamide derivatives as M3 muscarinic acetylcholine receptor antagonists. WOA2, Published on 05/26/2006; US**B2, granted on 04/26/2011